OR WAIT null SECS
Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.
On March 8, 2018, ProBioGen, a German service and technology provider for complex therapeutic glycoproteins, announced the signing of a second antibody development project with Surface Oncology, an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment.
Under this agreement, Surface Oncology will contract with ProBioGen to develop and manufacture an antibody for potential use in clinical trials. ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number, and conclude with process development and GMP manufacturing for a single antibody product candidate.
"We have worked together with Surface Oncology very well for quite a while and this is now our second potential clinical antibody project together. We have established a seamless team working across our companies and we are very pleased to continue to expand this relationship with Surface Oncology," said Dr. Gabriele Schneider, ProBioGen's chief business officer, in a company press release.